Study on Adding Apalutamide to Radiotherapy and LHRH Agonist for High-Risk Patients with Hormone-Sensitive Prostate Cancer

3 1 1 1

What is this study about?

This clinical trial is focused on studying a treatment for high-risk hormone-sensitive prostate cancer. The study is investigating the effectiveness and safety of adding a medication called Apalutamide to a combination of radiotherapy and a type of hormone therapy known as LHRH agonist. The goal is to see if this combination can delay the spread of cancer or death compared to using just radiotherapy and LHRH agonist alone. The study will use a special imaging technique called PSMA-PET to assess the cancer’s progression.

Participants in the study will receive either the combination of Apalutamide, radiotherapy, and LHRH agonist or just radiotherapy and LHRH agonist. The study will also include an observational group to gather additional information. Apalutamide is taken as a tablet by mouth, while radiotherapy is a treatment that uses high-energy rays to target cancer cells. The LHRH agonist is a type of hormone therapy that is given as an injection under the skin. The study will monitor participants over a period to observe the effects of the treatments.

The study aims to provide valuable insights into whether adding Apalutamide can improve outcomes for patients with high-risk hormone-sensitive prostate cancer. By using PSMA-PET, a type of imaging that helps visualize prostate cancer, researchers hope to better understand how the cancer responds to the treatment. This trial is an important step in exploring new ways to manage and treat prostate cancer effectively.

1 joining the study

Upon joining the study, the participant will have signed an informed consent form, indicating understanding and willingness to participate in the study.

The participant must be 18 years or older and have a confirmed diagnosis of high-risk recurrent prostate cancer previously treated with radical prostatectomy.

2 initial assessment

An initial assessment will be conducted to confirm eligibility, including a review of medical history and current health status.

The participant must have adequate organ function and be able to swallow the study drug tablets or follow instructions for admixing with apple sauce.

3 treatment phase

The treatment phase involves the administration of apalutamide in combination with radiotherapy and LHRH agonist.

Apalutamide is provided in the form of film-coated tablets for oral use. The dosage and frequency will be determined by the study protocol.

Participants receiving bone-loss prevention treatment must be on stable doses for at least 4 weeks before randomization.

4 monitoring and follow-up

Regular monitoring will be conducted to assess the participant’s response to treatment and any side effects.

The primary endpoint is PSMA-PET metastatic progression-free survival, which is the time from randomization to the date of metastatic progression or death from any cause.

5 end of treatment

The treatment phase will conclude as per the study protocol, and participants will be monitored for a specified period after the last dose of the study drug.

Participants must agree not to donate sperm for reproduction during the treatment phase and for a minimum of 3 months after the last dose.

Who Can Join the Study?

Must be a person aged 18 years or older.
Must have adequate organ function, which means:
- Levels of certain liver enzymes (AST and ALT) should be no more than 2.5 times the normal limit.
- Total bilirubin, a substance made by the liver, should be no more than 1.5 times the normal limit.
- Serum creatinine, a waste product in the blood, should be less than 1.8 mg/dL.
- Platelets, which help with blood clotting, should be at least 75,000 per microliter without recent transfusions or growth factors.
- Hemoglobin, a protein in red blood cells, should be at least 10.0 g/dL without recent transfusions or growth factors.
Must be able to swallow the study drug tablets or mix them with applesauce.
If engaging in sexual activity with a person who can become pregnant, a condom must be used along with another effective birth control method during the treatment and for 3 months after the last dose.
Must agree not to donate sperm for reproduction during the treatment and for at least 3 months after the last dose.
If receiving treatment to prevent bone loss, must be on stable doses for at least 4 weeks before starting the study.
Must be planned to receive a specific type of radiation therapy for prostate cancer.
Must sign an Informed Consent Form, showing understanding and willingness to participate in the study.
Must have a confirmed diagnosis of prostate cancer.
Must have been previously treated with a surgery called radical prostatectomy, with specific conditions related to PSA levels, a protein produced by the prostate.
Must be at high risk of cancer spreading, based on certain medical criteria like a high Gleason score, which is a grading system for prostate cancer.
Results from a specific scan called PSMA-PET must meet certain conditions regarding cancer lesions.
If there is evidence of cancer spread on a PSMA-PET scan, there must be no evidence of spread on other scans like CT, MRI, or bone scans. If a single bone lesion is found, it must be confirmed by another scan.
Must have a performance status of Grade 0 or 1, which means being fully active or having some symptoms but being able to carry out light work.

Who Cannot Join the Study?

Patients who have not been diagnosed with high risk recurrent prostate cancer that was previously treated with surgery to remove the prostate.
Patients who are female, as the study is only for male participants.
Patients who are part of a vulnerable population, which means groups that might need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Policlinico “Tor Vergata”, Università degli Studi di Roma TOR VERGATA	Rome	Italy
Azienda Ospedaliero Universitaria Careggi	Florence	Italy
Technische Universitaet Dresden	Dresden	Germany
Hospital Universitario Y Politecnico La Fe	Valencia	Spain
Hospital Universitario De Navarra	Pamplona	Spain
Szpital Wojewodzki Im. Mikolaja Kopernika W Koszalinie	Koszalin	Poland
Hospital Jerez de la Frontera	Jerez De La Frontera	Spain

Other Sites

Site Name	City	Country
Ospedale San Raffaele S.r.l.	Milan	Italy
Hospital Da Luz S.A.	Lisbon	Portugal
Az St-Jan Brugge-Oostende A.V.	Brugge	Belgium
Instituto Portugues De Oncologia De Lisboa Francisco Gentil E.P.E.	Lisbon	Portugal
Urocentrum Praha s.r.o.	Prague	Czechia
Uztmvfxrmg Oy Dgxbsfti	Debrecen	Hungary
Sdiqbzwhpjjttch Ab	Stockholm	Sweden
Bxtbepgcj Ufockl Uwsqz Kdjimf	Budapest	Hungary
Vekvgd drc Rtahk Uoxktwfxmn Hpiwejqp	Sevilla	Spain
Fddivcxm nnpemmlwd Mcjov a Hqhaqrf	Prague	Czechia
Htfoyz Hxfwnbyu	Herlev	Denmark
Rzgshx Sbanv Ssyeue Uaxtecjeeriwcmzxtan	Lund	Sweden
Hkbwqbjc Uqkinyvyut Chmwrjr Hohjpsmb	Helsinki	Finland
Utitxbojftdamupitzstz Mkklukcq Auq	Munster	Germany
Awlxaip Uaotxjyhwa Hhakjxeg	Aalborg	Denmark
Gsmtrutmjdiahah Anvlsryit	Antwerp	Belgium
Shyux Gbgzqb Slzimzk	Stockholm	Sweden
Rxhorvipgdhwdt	Copenhagen	Denmark
Ajfhnpk Uhvxv Swzlwyhop Ldcxjb Do Bayzkcd	Bologna	Italy
Uzuftyetybkjtc Cehggaw Knirgpyne	Gdansk	Poland
Kamafyji doc Tratztryhda Usiznbwcutme Mcvtkkew (qoi Klrrnlupl	Munich	Germany
Uvqqutegfuqehtvoikrjh Eavsj Aog	Essen	Germany
Iyhjqm Icyvgpns Fsiyyttiszrut Osljjmiwtba	Rome	Italy
Oatryajduexjdh Lvnf Gbje	Linz	Austria
Upkpoeeklypn Zivguvvxtw Gyka	Gent	Belgium
Hdvchovy Usmhvzlbcydnw 1l Df Ojxekqy	Madrid	Spain
Fqdgzjzif Pjon Li Icyfwtyljpdss Bvhiefpzs Dpc Hnukvvao Uirelylmtkbuq Lz Poc	Madrid	Spain
Wduxdgzmwuv Wjjivewhajxiqrsdmkoa Cuexnac Oqjoaruqn I Tzzlpevkcgttr Ig Mfamkxehfdy W Lmfbc	Lodz	Poland
Akpmbicx Zqjhffpwyx Gzlavgnpe	Kortrijk	Belgium
Uxwxuvkynxh Ndptkpfsd Mypcix	Martin	Slovakia
Swpmxmqu Pukzmzefv Snt z ofqi	Gdynia	Poland
Hkplthtq Cudqtpu Uepmnmqndgbmn Lkncyx Bloht	Zaragoza	Spain
Hzzygalo Udiniwfgldcrp Vtijya Dz Lc Vfufsgma	Malaga	Spain
Upnoloyhvyh Sjrfteod	Salzburg	Austria
Fualzdvm Nywqpbnir Pjiqa	Plzen	Czechia
Eaizavmfzdz Soqjj Jluio Ckqfmihpqcvxu	Budapest	Hungary
Onnpjeny Oxaucrhmun Ipfofke	Budapest	Hungary
Vvoqtqghneledmbo hfreambwtvheskr	Turku	Finland
Np Mao Gyjgc Sbeg	Elblag	Poland
Pwzhezwizhewlxzdxr hkbkfokaqzsryuc	Oulu	Finland
Beezocoxsvahuashg Kumjna Ex Rvbopvlgbhxnwu	Budapest	Hungary
Uxyykmz saiwp s rcyl	Nitra	Slovakia
Aoridz Uypugbkygj Hcndauiu	Aarhus	Denmark
Cyttxzilwtqe Cmomvzpp Crpfkt	Lisbon	Portugal
Mqfmfnqv suqude	Presov	Slovakia
Hgcugwwe Cml Twsh Sucd	Lisbon	Portugal
Srxkvsaqhmvwwg Cqbcbqy Oqhzwfszc Sxqgzvqrbgq Pvxgbhqou Zlemrf Ofpigd Zykpltcxrj W Kdrbihju	Kielce	Poland
Jmsy Fnqrjg Dwrzzcfyb Keouor Eo Rerwxbebggvnwl	Budapest	Hungary
Kfzypqw Ngzdjhqcbrosqbdctze Sgm z obwd	Radom	Poland
Phoatzbkpz hjiahbdtvhmenqg	Tampere	Finland
Cewlipt Obbhflzei Irq Pxarn Fjovjbyfvs Lqwdxkpmjyr W Bmkilqvtsl	Bydgoszcz	Poland
Asaozvj Ojiywucvmlquwjwljcnondrft Sdfj Apnwu	Rome	Italy
Suhrlepntzwm Kfceldaz Boehssreczmr gxlir	Brunswick	Germany
Vopznlar Nwcvhhcy fqeg Gkdccpjylt Gmwv	Berlin	Germany
Hnwppylc Usnbpqjiorlth Pqryhw Dpr Mzb	Cadiz	Spain
Huntbwvt Dn Shyfb Mojzr Exhkyk	Lisbon	Portugal
Arkh Sylricupl Do Fbsqtv	Ferrol	Spain
Vcnaiyyxdbyyzgel Ojhabzutvuc Usfzi adkn	Kosice	Slovakia
Uondtzk Lokjq Dy Skoup Dg Euepc O Duccq E Vvrjw Epkfhj	Santa Maria Da Feira	Portugal
Vvnov Ccwpwzz Hyadjccq	Vaasa	Finland
Pxsfnjtw Uioikylduv Ampmioknca smqryn	Trencin	Slovakia
Nvooslnr Iuysyykp Otsywxefi Irc Mqaga Sdrlsqmdghoioddxqgulhzckggnr Itpqxftr Bqxzrwmm	Warsaw	Poland
Cszkid Hgupmtjchn Ulbbvnvcwiznl Dh Panri Ewjonm	Porto	Portugal
Vcvyuhlay Fchkubgk Njxthkvzk V Pulhy	Prague	Czechia

Trial status

Country	Status	Recruitment Start
Austria	Not recruiting	17.11.2020
Belgium	Not recruiting	17.11.2020
Czechia	Not recruiting	17.11.2020
Denmark	Not recruiting	17.11.2020
Finland	Not recruiting	17.11.2020
Germany	Not recruiting	17.11.2020
Hungary	Not recruiting	17.11.2020
Italy	Not recruiting	17.11.2020
Poland	Not recruiting	17.11.2020
Portugal	Not recruiting	17.11.2020
Slovakia	Not recruiting	17.11.2020
Spain	Not recruiting	17.11.2020
Sweden	Not recruiting	17.11.2020

Trial locations

Investigated Drugs:

Apalutamide

Apalutamide is a medication used in this trial to treat high-risk patients with hormone-sensitive prostate cancer. It works by blocking the effects of male hormones that can promote the growth of cancer cells. The study aims to see if adding apalutamide to the standard treatment can delay the spread of cancer or death.

Radiotherapy (RT) is a treatment that uses high-energy rays to target and kill cancer cells. In this trial, it is used as part of the standard treatment for prostate cancer to help control the disease and reduce the risk of it spreading.

LHRH Agonist is a type of hormone therapy used to lower the levels of male hormones in the body, which can help slow down or stop the growth of prostate cancer cells. It is part of the standard treatment in this trial, combined with radiotherapy, to manage hormone-sensitive prostate cancer.

Prostate Cancer – Prostate cancer is a disease where cells in the prostate gland grow uncontrollably. It often progresses slowly and may not show symptoms in the early stages. As it advances, it can cause urinary problems, pelvic discomfort, or bone pain. The cancer can spread to other parts of the body, such as bones and lymph nodes. The progression is typically monitored through imaging tests and blood markers. Treatment aims to manage the disease and prevent further spread.

Trial ID:

2023-505852-23-00

Protocol code:

56021927PCR3015

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Adding Apalutamide to Radiotherapy and LHRH Agonist for High-Risk Patients with Hormone-Sensitive Prostate Cancer

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?